In patients with prostate cancer, prior research has shown that germline BRCA mutations have a negative effect on outcomes. However, the connection between somatic and germline mutations in homologous recombination repair (HRR) genes and treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. A study from David Olmos, MD, PhD, and Elena Castro, MD, PhD, sought to determine the outcomes and prevalence related to somatic or germline HRR alterations, specifically BRCA1/2, in patients beginning first-line treatment with androgen receptor signaling inhibitors or taxanes for mCRPC. ...